Tags

Type your tag names separated by a space and hit enter

Assessment of urinary gonadotropin in solid carcinomas other than gynecological tumors.
J Clin Lab Anal. 1996; 10(4):184-92.JC

Abstract

To the already long list of existing tumor markers, a new marker has been recently added, the urinary gonadotropin peptide (UGP). This marker is determined in the urine of cancer patients and is considered to be particularly specific for ovarian carcinomas. The purpose of our study was to assess the specificity of UGP in a variety of malignancies other than ovarian carcinomas, e.g., breast, colonic, lung, and urogenital tumors (n = 50 each). The tumors were compared with benign lesions of the same organs. Urine samples of 50 healthy donors served as controls. The 450 urine samples were tested in duplicate using the UGP EIA-kit from Ciba Corning Diagnostics. All tumors were staged and histologically classified. For normalization in all samples, creatinine levels were determined. UGP was found in all tested tumors, however, with very low sensitivity of 20% in urogenital tumors, 46% in lung, and 30% or 27% in colon and breast carcinomas, respectively. The specificity of UGP was comprised between 100% (breast) and 88%. Clearly elevated UGP-concentrations were seen in postmenopausal women. A comparison of UGP with the optimal markers for each tumor system showed that UGP is not superior to these markers. However, we can confirm UGP as being an optimal marker for gynecological carcinomas.

Authors+Show Affiliations

Institute of Immunology of the University, Medical Faculty, Freiburg, Germany.No affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

8811461

Citation

von Kleist, S, et al. "Assessment of Urinary Gonadotropin in Solid Carcinomas Other Than Gynecological Tumors." Journal of Clinical Laboratory Analysis, vol. 10, no. 4, 1996, pp. 184-92.
von Kleist S, Walker B, Walker R. Assessment of urinary gonadotropin in solid carcinomas other than gynecological tumors. J Clin Lab Anal. 1996;10(4):184-92.
von Kleist, S., Walker, B., & Walker, R. (1996). Assessment of urinary gonadotropin in solid carcinomas other than gynecological tumors. Journal of Clinical Laboratory Analysis, 10(4), 184-92.
von Kleist S, Walker B, Walker R. Assessment of Urinary Gonadotropin in Solid Carcinomas Other Than Gynecological Tumors. J Clin Lab Anal. 1996;10(4):184-92. PubMed PMID: 8811461.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Assessment of urinary gonadotropin in solid carcinomas other than gynecological tumors. AU - von Kleist,S, AU - Walker,B, AU - Walker,R, PY - 1996/1/1/pubmed PY - 2000/6/20/medline PY - 1996/1/1/entrez SP - 184 EP - 92 JF - Journal of clinical laboratory analysis JO - J Clin Lab Anal VL - 10 IS - 4 N2 - To the already long list of existing tumor markers, a new marker has been recently added, the urinary gonadotropin peptide (UGP). This marker is determined in the urine of cancer patients and is considered to be particularly specific for ovarian carcinomas. The purpose of our study was to assess the specificity of UGP in a variety of malignancies other than ovarian carcinomas, e.g., breast, colonic, lung, and urogenital tumors (n = 50 each). The tumors were compared with benign lesions of the same organs. Urine samples of 50 healthy donors served as controls. The 450 urine samples were tested in duplicate using the UGP EIA-kit from Ciba Corning Diagnostics. All tumors were staged and histologically classified. For normalization in all samples, creatinine levels were determined. UGP was found in all tested tumors, however, with very low sensitivity of 20% in urogenital tumors, 46% in lung, and 30% or 27% in colon and breast carcinomas, respectively. The specificity of UGP was comprised between 100% (breast) and 88%. Clearly elevated UGP-concentrations were seen in postmenopausal women. A comparison of UGP with the optimal markers for each tumor system showed that UGP is not superior to these markers. However, we can confirm UGP as being an optimal marker for gynecological carcinomas. SN - 0887-8013 UR - https://www.unboundmedicine.com/medline/citation/8811461/Assessment_of_urinary_gonadotropin_in_solid_carcinomas_other_than_gynecological_tumors_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0887-8013&date=1996&volume=10&issue=4&spage=184 DB - PRIME DP - Unbound Medicine ER -